Results 261 to 270 of about 4,276,711 (338)

Update on Non‐Biological and RNA‐Based Therapeutics in Chronic Inflammatory Diseases: Precision Medicine Through Small Molecules: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT In the last decades, critical advancements in research technology and knowledge on disease mechanisms steered therapeutic approaches for chronic inflammatory diseases towards unprecedented target specificity. For allergic and chronic lung diseases, biologic drugs pioneered this goal, acquiring on the way—through the clinical use of monoclonal ...
F. Roth‐Walter, I. M. Adcock, C. Benito‐Villalvilla, R. Bianchini, L. Bjermer, G. Caramori, L. Cari, K. F. Chung, Z. Diamant, I. Eguiluz‐Gracia, E. F. Knol, M. Jesenak, F. Levi‐Schaffer, G. Nocentini, L. O'Mahony, O. Palomares, F. Redegeld, M. Sokolowska, B. Van Esch, M. Zurlo, C. Stellato   +20 more
wiley   +1 more source

Venous thromboembolism risk following surgery during the COVID‐19 pandemic

Anaesthesia, EarlyView.
Summary Introduction SARS‐CoV‐2 infection is associated with an increased risk of venous thromboembolism. Data are lacking on how this risk altered during the COVID‐19 pandemic and following vaccination. We aimed to evaluate the 90‐day risk of postoperative venous thromboembolism during the pandemic. Methods We performed a retrospective cohort study of
Andrew Jackson, David J. Humes, Amir Mehrkar, Sebastian C. J. Bacon, Simon Davy, Ben Goldacre, Joe West, Colin J. Crooks   +7 more
wiley   +1 more source

Significance of bovine coronavirus infection

Veterinary Record, 1978
G N, Woode, J C, Bridger, A, Meyling
openaire   +2 more sources

Zanamivir and baloxavir combination to cure persistent influenza and coronavirus infections after hematopoietic stem cell transplant. [PDF]

Int J Antimicrob Agents
Euzen V, Xhaard A, Berreira-Ibraim S, Deville L, Quentin A, De Lima Prata PH, Gournay V, Prot M, Rahou Y, Barbet M, Mercier-Delarue S, Peffault De La Tour R, Simon-Loriere E, Legoff J.   +13 more
europepmc   +1 more source

Vaccinations During Pregnancy Protect the Mother–Infant Dyad and Are Generally Safe

Acta Paediatrica, EarlyView.
ABSTRACT Aim Vaccination in pregnancy has a critical impact on mothers, foetuses and infants. The aim of this paper was to summarise key points presented by experts attending the 12th Maria Delivoria‐Papadopoulos Perinatal Symposium in March 2025 and further expand and update them.
Ariadne Malamitsi‐Puchner, Despina D. Briana, Gian Carlo Di Renzo   +2 more
wiley   +1 more source

In for a penny: An empirical study of earthquake experience and non‐pharmaceutical intervention effectiveness in the Marche region

Annals of Public and Cooperative Economics, EarlyView.
Abstract This study investigates whether prior exposure to natural disasters influenced individual compliance with non‐pharmaceutical interventions (NPIs), specifically lockdown measures, during the Corona Virus Infectious Disease 2019 (COVID‐19) pandemic. Focusing on the Marche region of Italy, which experienced a severe earthquake in 2016, we exploit
Vincenzo Alfano, Salvatore Capasso, Salvatore Ercolano   +2 more
wiley   +1 more source

Endemic Coronavirus Infections are Associated with Strong Homotypic Immunity in a US Cohort of Children from Birth to 4 Years. [PDF]

J Pediatric Infect Dis Soc
Morrow AL, Payne DC, Conrey SC, McMorrow M, McNeal MM, Niu L, Burrell AR, Schlaudecker EP, Mattison C, Burke RM, DeFranco E, Teoh Z, Wrammert J, Atherton LJ, Thornburg NJ, Staat MA.   +15 more
europepmc   +1 more source

Inactivated Split MERS-CoV Antigen Prevents Lethal Middle East Respiratory Syndrome Coronavirus Infections in Mice. [PDF]

Vaccines (Basel)
Seo H, Jang Y, Kwak D.
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source